- Home
- DOCS vs RNA Comparison
DOCS vs RNA Comparison
Compare DOCS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCS | RNA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOCS | RNA |
|---|---|---|
| Price | $25.14 | $72.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | $52.26 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 4.4M | 2.6M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.17 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $570,399,000.00 | $18,755,000.00 |
| Revenue This Year | $15.08 | $88.12 |
| Revenue Next Year | $9.60 | $18.11 |
| P/E Ratio | $27.73 | ★ N/A |
| Revenue Growth | 19.98 | ★ 72.11 |
| 52 Week Low | $23.53 | $25.28 |
| 52 Week High | $76.51 | $73.06 |
Technical Indicators
Market Signals| Indicator | DOCS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 26.28 | 57.52 |
| Support Level | $23.65 | $70.42 |
| Resistance Level | $46.72 | $73.04 |
| Average True Range (ATR) | 1.47 | 0.19 |
| MACD | 0.22 | -0.06 |
| Stochastic Oscillator | 31.45 | 38.27 |
Price Performance
Historical ComparisonAbout DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.